Cell Genesys GVAX Prostate Cancer Vaccine Will Begin Phase III Under Special Protocol Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trial program will attempt to demonstrate superiority over taxane chemotherapy in treating hormone-refractory metastatic prostate cancer patients. Cell Genesys hopes to highlight tolerability, dosing convenience of vaccine if approved.